ArticleThe oncologist2025

Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer.

Rithika Rajendran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.